This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pulmonary Valve Atresia폐동맥판폐쇄

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q22.0 | Special Copayment Reduction: V145 (rare disease Special Copayment Reduction)
B. SynonymsPulmonary valve atresia, Pulmonary Atresia (PA), PA+IVS (pulmonary atresia with intact ventricular septum), PA+VSD (pulmonary atresia with ventricular septal defect)
C. Adult onsetLikelihood of first onset in adulthood very low — a ductus-dependent cyanotic congenital heart disease that almost without exception requires diagnosis and management in the neonatal period. Most untreated patients die in infancy. Those who survive into adulthood are patients under postoperative follow-up or have rare exceptional anatomy (pulmonary blood flow maintained by large MAPCAs).
1. History19th-century autopsy descriptions → 1944 BT shunt → introduction of PGE1 (1970s) → balloon perforation for PA+IVS → advances in MAPCA unifocalization surgery.
2. CausesComplete atresia of the right ventricular outflow tract. PA+VSD (extreme form of conotruncal anomaly, with MAPCAs) vs PA+IVS (poor right ventricular development, RVDCC). Without PGE1, death from ductal closure.
3. GeneticsPA+VSD: 22q11.2 deletion in 15–20% (similar to TOF). PA+IVS: mostly sporadic. Association with Noonan syndrome reported. CMA/FISH performed in all patients.
4. General epidemiology1–3% of congenital heart disease. The representative ductus-dependent cyanotic congenital heart disease. PGE1 essential immediately at birth. Korea Q22.0, Special Copayment Reduction V145.
5. PathophysiologyPulmonary blood flow = dependent on PDA or MAPCAs. PA+IVS: small right ventricle, right ventricle-to-coronary artery fistulas (RVDCC). Loss of pulmonary blood flow when the ductus closes → severe cyanosis and acidosis.
6. SymptomsNeonatal cyanosis (extremely low SpO2). Rapid worsening of cyanosis when the ductus closes. Poor response to oxygen. Immediate stabilization with PGE1 administration.
7. SignsCentral cyanosis, extremely low oxygen saturation. No murmur or continuous murmur (PDA/MAPCA). Echocardiography: pulmonary valve atresia, right ventricular size, RVDCC. CT: MAPCA anatomy.
8. ScreeningNewborn CCHD oxygen saturation screening (SpO2<95%). Prenatal fetal echocardiography (18–22 weeks). Planning for specialist team deployment before delivery.
9. DiagnosisEchocardiography (pulmonary valve atresia, right ventricular size, RVDCC). Cardiac CTA (MAPCA anatomy, pulmonary artery branches). Cardiac catheterization (right ventricular pressure, assessment of coronary branches). 22q11.2 testing.
10. TreatmentImmediate PGE1 administration (maintain the ductus). PA+IVS: depending on right ventricular size, percutaneous perforation (biventricular surgery) or the single-ventricle Fontan pathway. PA+VSD+MAPCA: unifocalization surgery + conduit insertion.
11. PrognosisCompletely repaired PA+VSD: 5–10-year survival 70–85%. PA+IVS Fontan: 60–75% at 10 years. Presence of RVDCC and complexity of MAPCA anatomy are the main prognostic factors.
12. PreventionPrenatal diagnosis → delivery planned at a specialized center. PGE1 immediately at birth. Multidisciplinary management of noncardiac complications of 22q11.2 deletion. Regular postoperative follow-up of conduits and MAPCAs.
13. ReferencesList of 10 key references

1. History

Pulmonary Valve Atresia (PA) is a rare congenital heart disease in which the pulmonary valve is completely closed so that blood cannot flow out of the right ventricle into the pulmonary artery by the normal route. The first descriptions of this disease were made in the early 19th century, centered on autopsy findings.

Modern understanding progressed with advances in echocardiography and cardiac catheterization in the 1940s–50s. With the introduction of the Blalock-Taussig shunt (BT shunt) in 1944, palliative surgery became possible even in PA patients with ductus-dependent pulmonary circulation. In the 1970s, complete repair (right ventricular outflow tract reconstruction or conduit insertion) was attempted, and surgical outcomes subsequently improved as techniques advanced.

PA is classified into two types according to the status of the ventricular septum. PA with VSD (pulmonary valve atresia + ventricular septal defect, the extreme form of tetralogy of Fallot) and PA with IVS (pulmonary valve atresia + intact ventricular septum) have different pathophysiology and treatment pathways. In PA+IVS, the ventricular septum is intact, the right ventricle is extremely underdeveloped, and right ventricle-to-coronary artery fistulas are common.

The introduction of prostaglandin E1 (PGE1) (1970s) became the key medical means of keeping the ductus arteriosus open to maintain pulmonary blood flow, bringing revolutionary change to the stabilization and surgical planning of neonatal PA patients. Subsequently, catheter-based interventions such as percutaneous pulmonary balloon valvuloplasty and laser pulmonary valve perforation (radiofrequency perforation) developed, establishing an approach of growing the right ventricle in PA+IVS patients.


2. Causes

Pulmonary valve atresia results from abnormal development of the pulmonary valve and right ventricular outflow tract during embryonic development. In PA+VSD (the extreme form of tetralogy of Fallot), severe deviation of the conotruncal septum completely occludes the right ventricular outflow tract, and the pulmonary valve does not form. Pulmonary blood flow is maintained through the ductus arteriosus (PDA) or major aortopulmonary collateral arteries (MAPCA).

In PA+IVS, the abnormal development of the right ventricle is more severe, and the right ventricle is very small. The tricuspid valve is also narrow or functions poorly, and sinusoidal communications between the right ventricle and the coronary arteries (right ventricle-to-coronary artery fistulas, ventriculocoronary connections) often develop. In some, there is right ventricle-dependent coronary circulation (RVDCC), so coronary ischemia can occur with right ventricular decompression, which greatly changes the treatment direction.

Among genetic causes, 22q11.2 deletion is found at relatively high frequency in PA+VSD, and variants of genes such as NKX2.5 and GATA4 have also been reported. The genetic cause of PA+IVS has not been clearly established to date. Among environmental factors, diabetes in early pregnancy, retinoid exposure and others are known as general risk factors for congenital heart disease.


3. Genetics

The genetics of pulmonary valve atresia are understood differently for PA+VSD and PA+IVS. PA+VSD is an extreme form of conotruncal anomaly similar to TOF; 22q11.2 deletion (TBX1) is found in about 15–20%, and it shares a genetic basis similar to TOF. In PA+VSD patients with 22q11.2 deletion, DiGeorge syndrome-related noncardiac abnormalities (hypocalcemia, immunodeficiency, palatal anomalies) may be present.

The genetic causes of PA+IVS are not well known to date, and most cases occur sporadically. The risk of recurrence within a family is estimated to be low. Co-occurrence of Noonan syndrome (PTPN11, SOS1 and other variants) has been reported in some PA+IVS patients; in Noonan syndrome, pulmonary stenosis is the most common cardiac anomaly, but some cases progress to PA. It is recommended that 22q11.2 deletion testing (FISH/CMA) and chromosomal microarray be performed in all PA patients.


4. General epidemiology

Pulmonary valve atresia accounts for about 1–3% of all congenital heart disease. This is the combined frequency of PA+VSD (including MAPCA) and PA+IVS. It is estimated to occur in about 1 in 7,000–10,000 live births. No significant sex difference has been reported.

In Korea, it is classified under code Q22.0 and registered as eligible for Special Copayment Reduction V145. A certain number of neonatal PA patients undergo surgery every year at specialized pediatric cardiac surgery centers in Korea. PA is a representative form of ductus-dependent congenital heart disease, and severe cyanosis and shock develop within hours to days after birth as the ductus arteriosus closes. Therefore, emergency management in the neonatal period (PGE1 administration) and immediate referral to specialized pediatric cardiology care determine survival.

PA+VSD with MAPCAs is particularly complex and requires multistage surgery including unifocalization and conduit surgery. On long-term follow-up, reoperations due to conduit stenosis or regurgitation tend to be repeated.


5. Pathophysiology

The core pathophysiology of pulmonary valve atresia is that the right ventricular outflow tract is completely blocked, so that immediately after birth pulmonary blood flow depends entirely on the ductus arteriosus (PDA) or MAPCAs. Because the ductus arteriosus closes naturally after birth, without treatment pulmonary blood flow is lost within hours to days, leading to severe cyanosis, metabolic acidosis and death.

In PA+IVS, because there is no forward flow between the right ventricle and the pulmonary artery, the right ventricle does not receive a developmental stimulus, and a small, underdeveloped right ventricle (hypoplastic RV) forms. The tricuspid valve is also small or dysfunctional. Because pressure within the right ventricle is very high, fistulas with the coronary arteries (sinusoidal communications) develop, and right ventricle-dependent coronary circulation (RVDCC), in which some coronary blood flow depends on the right ventricle, results. In this case, decompressing the right ventricle (after pulmonary valve perforation) can cause coronary ischemia, so in some cases the single-ventricle surgical pathway (Fontan) is appropriate.

In PA+VSD (with MAPCAs), the major aortopulmonary collateral arteries supply blood irregularly to lung segments, and the anatomic arrangement of these collaterals is of key importance for surgical planning (unifocalization).


6. Symptoms

The clinical symptoms of pulmonary valve atresia appear within hours to days after birth. As the ductus arteriosus closes spontaneously, sudden worsening of cyanosis, tachypnea, hyperpnea, refusal to feed, decreased consciousness and metabolic acidosis occur.

Neonatal period: cyanosis is the most characteristic symptom of PA. In the ductus-dependent state, cyanosis worsens rapidly when the ductus closes. Failure to respond, or only a very limited response, to oxygen is characteristic of ductus-dependent cyanotic congenital heart disease. In this state, reopening the ductus with immediate PGE1 administration is the first life-saving measure.

In PA+VSD with MAPCAs, the collaterals supply some pulmonary blood flow, so initial cyanosis may be less severe, but the clinical picture varies with the size and distribution of the collaterals. Heart failure may appear with excessive pulmonary blood flow, and severe cyanosis with insufficient pulmonary blood flow.


7. Signs

On physical examination, central cyanosis, decreased oxygen saturation (SpO2 < 70–80%) and rapid breathing are characteristic. A continuous murmur due to the ductus arteriosus or a nonspecific murmur due to MAPCAs may be heard. In simple PA, there may be no murmur.

Electrocardiogram: normal neonatal pattern or right axis deviation, right ventricular hypertrophy (small right ventricle in PA+IVS). In PA+VSD, findings of right ventricular hypertrophy similar to TOF. Chest X-ray: decreased pulmonary vascular markings in PA+VSD, with normal or reduced cardiac silhouette. Cardiomegaly in PA+IVS (when tricuspid regurgitation is severe). Echocardiography: confirms pulmonary valve atresia (atresic valve), obstruction of the right ventricular outflow tract, right ventricular size, tricuspid valve size and function, presence and direction of the ductus arteriosus, and presence of MAPCAs. Cardiac CTA: essential for evaluating the anatomic arrangement of MAPCAs and the structure of the pulmonary artery branches.


8. Screening

Pulmonary valve atresia is a cyanotic congenital heart disease and a major target of newborn CCHD oxygen saturation screening. SpO2 < 95% within 24–48 hours after birth or a difference > 3% between right hand and foot SpO2 is the positive criterion, and the diagnosis is confirmed immediately by echocardiography. On prenatal fetal echocardiography (18–22 weeks of gestation), absent flow in the right ventricular outflow tract, an undeveloped pulmonary valve and reduced right ventricular size raise suspicion of PA. When there is a risk of 22q11.2 deletion, prenatal FISH/CMA is recommended.


9. Diagnosis

Diagnosis is based on echocardiography, but cardiac CTA or cardiac catheterization is essential to identify the sources of pulmonary blood flow (ductus arteriosus, MAPCA). Echocardiography: confirmation of pulmonary valve atresia, right ventricular size (tricuspid annulus diameter Z-score), right ventricular function, presence and direction of the ductus arteriosus (left→right or right→left), tricuspid valve size and regurgitation, presence of right ventricle-to-coronary artery fistulas. Cardiac CT: three-dimensional evaluation of the number, size, origin and distribution to lung segments of MAPCAs. Confirmation of pulmonary artery branch structure. Cardiac catheterization: right ventricular pressure, confirmation of right ventricle-to-coronary artery fistulas, pulmonary vascular resistance, evaluation of pulmonary artery branch structure. 22q11.2 deletion testing is performed in all PA+VSD patients.


10. Treatment

The first step in treating pulmonary valve atresia is maintaining the ductus arteriosus with continuous intravenous prostaglandin E1 (PGE1) in the neonatal period. The treatment pathway for PA+IVS is determined by right ventricular size. When the right ventricle is sufficiently developed: percutaneous pulmonary valve perforation (radiofrequency perforation + balloon valvuloplasty) opens the right ventricular outflow tract to grow the right ventricle and avoid diastolic single-ventricle physiology. When the right ventricle is poorly developed or RVDCC is present: the single-ventricle surgical pathway (BDG → Fontan) is chosen. Pulmonary blood flow is secured with a BT shunt or a right ventricle-to-pulmonary artery shunt.

Treatment of PA+VSD+MAPCA: unifocalization: a complex multistage operation in which the MAPCAs are surgically gathered into one place and connected to the native pulmonary arteries, and a right ventricle-to-pulmonary artery conduit is inserted. The goal is VSD repair and complete repair. The Stanford-style staged unifocalization approach is widely used. Conduits require replacement with growth, and transcatheter pulmonary valve replacement (TPVR) is used as an alternative to reoperation.


11. Prognosis

The prognosis of pulmonary valve atresia varies according to PA+VSD versus PA+IVS, the degree of right ventricular development, MAPCA anatomy and the completeness of surgery. The 5–10-year survival of PA+VSD patients who have undergone complete repair at specialized centers is reported at 70–85%. In PA+IVS following the single-ventricle Fontan surgical pathway, 10-year survival is about 60–75%.

In PA+VSD with MAPCAs, the completeness of unifocalization and residual lesions (pulmonary artery branch stenosis, residual VSD shunt, conduit stenosis) determine long-term prognosis. Repeated conduit replacement surgery or percutaneous interventions are needed. In PA+IVS with RVDCC, the prognosis is worse, and even after single-ventricle surgery, myocardial damage due to coronary ischemia can be a problem.


12. Prevention

There is no established way to prevent the occurrence of pulmonary valve atresia itself; early detection through prenatal diagnosis and newborn CCHD screening and immediate management are the core of preventive management.

When PA is diagnosed on prenatal fetal echocardiography, delivery is planned before birth at a hospital with a specialized pediatric cardiac team, and a system for PGE1 administration and echocardiographic confirmation immediately at birth is prepared. Immediate PGE1 administration after birth is the key emergency measure that maintains ductus-dependent survival. Long-term postoperative follow-up (conduit stenosis, MAPCA restenosis, pulmonary artery pressure, ventricular function) is performed regularly at an ACHD specialty center. Patients with 22q11.2 deletion also receive multidisciplinary management of noncardiac complications.


13. References

  1. Freedom RM, Nykanen DG, Benson LN. The physiology of malformations of the right ventricular outflow tract. Pediatr Cardiol. 1992;13(2):117-122. DOI: 10.1007/BF00807029. PMID: 1594140.

  2. Stellin G, Vida VL, Milanesi O, et al. Surgical treatment of complex cardiac anomalies: the 'one and one half ventricle repair'. Eur J Cardiothorac Surg. 1999;15(4):436-443. DOI: 10.1016/S1010-7940(99)00049-0. PMID: 10371559.

  3. Hanley FL, Sade RM, Blackstone EH, et al. Outcomes in neonatal pulmonary atresia with intact ventricular septum: a multiinstitutional study. J Thorac Cardiovasc Surg. 1993;105(3):406-423. PMID: 8445920.

  4. Reddy VM, Liddicoat JR, Hanley FL. Midline one-stage complete unifocalization and repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collaterals. J Thorac Cardiovasc Surg. 1995;109(5):832-844. DOI: 10.1016/S0022-5223(95)70312-6. PMID: 7739250.

  5. Bull C, Kostelka M, Sorensen K, de Leval M. Outcome measures for the neonatal management of pulmonary atresia with intact ventricular septum. J Thorac Cardiovasc Surg. 1994;107(2):359-366. PMID: 8302059.

  6. Dyamenahalli U, McCrindle BW, McDonald C, et al. Pulmonary atresia with intact ventricular septum: management of, and outcomes for, a cohort of 210 consecutive patients. Cardiol Young. 2004;14(3):299-308. DOI: 10.1017/S1047951104003063. PMID: 15680049.

  7. Powell AJ, Geva T. Blood flow measurement by magnetic resonance imaging in congenital heart disease. Pediatr Cardiol. 2000;21(1):47-58. DOI: 10.1007/s002469910006. PMID: 10672613.

  8. Ashburn DA, Blackstone EH, Wells WJ, et al. Determinants of mortality and type of repair in neonates with pulmonary atresia and intact ventricular septum. J Thorac Cardiovasc Surg. 2004;127(4):1000-1007. DOI: 10.1016/j.jtcvs.2003.08.034. PMID: 15052196.

  9. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.

  10. Schneider M, Zartner P, Sidiropoulos A, Konertz W, Hausdorf G. Stent implantation of the arterial duct in newborns with duct-dependent circulation. Eur Heart J. 1998;19(9):1401-1409. DOI: 10.1053/euhj.1998.1061. PMID: 9792262.